摘要
淋巴水肿按发病因素可分为:原发性和继发性二大类,继发性淋巴水肿是由丝虫感染、外伤、手术创伤、大剂量放疗等诸多后天因素导致的淋巴回流障碍性疾病,以组织间隙的高蛋白水肿为特征,至今仍是医学领域的一个难题。长期以来,国内、外在临床上治疗淋巴水肿的方法主要是绷带捆扎、按摩、针灸、理疗等物理疗法或手术等,但这些方法只能起到短期缓解作用,都不能从根本上治愈淋巴水肿。从根本上解决问题的方法只有促进淋巴管的新生,新生的淋巴管才能促进淋巴回流,减轻淋巴水肿。
血管内皮生长因子(vascular endothelial growth factor,VEGF)家族是特异性作用于脉管内皮细胞的生长因子,其结构、功能相似,基因结构与血小板源性生长因子(PDGF)高度同源,其参于形成链间和链内二硫键的8个半胱氨酸是保守的。该家族包括VEGF-A(即传统意义上的VEGF)、VEGF-B、VEGF-C、VEGF-D、VEGF-E以及胎盘源性生长因子(PIGF)等,他们的生物学效应是由三个表达于特定细胞表面的受体来介导的:VEGFR-1(Flt-1),VEGFR-2(KDR或Flk-1)和VEGFR-3(Flt-4);传统理论认为VEGF-A与细胞表面受体VEGFR-1,VEGFR-2结合,特异性促进血管新生,VEGF-C在不同蛋白酶解下与细胞表面受体VEGFR-2或VEGFR-3结合,在不同条件下可促进淋巴管新生或血管新生。
根据VEGF-C可以选择性诱导淋巴管增生这一功能,我们不难推测,利用VEGF-C基因治疗淋巴管生成缺陷性疾病以及淋巴管阻塞导致的淋巴回流障碍性疾病应该是可行的。目前关于利用VEGF-C选择性诱导淋巴管增生的功能探讨淋巴水肿治疗的研究已有相关报道:Marika J等探讨了一种人类原发性淋巴水肿的基因治疗模型:通过病毒介导VEGF-C基因的治疗发现VEGF-C可以在模型小鼠皮肤中产生有功能的淋巴管,提示生长因子的基因治疗对人类的淋巴水肿治疗是可行的。因此我们设计推断VEGF-C同样可应用于基因治疗淋巴管生成缺陷性疾病如淋巴水肿,而用于基因治疗研究的关键性物质基础则是VEGF-C基因的真核表达载体。
因此,自1999年起,本课题组针对VEGF-C在肿瘤淋巴转移中的生物学功能及其应用方面开始了一系列研究,运用分子生物学技术构建了VEGF-C基因的真核表达载体并发表了相关的论文,为了获得VEGF-C对于淋巴管内皮细胞的调节作用和在淋巴管生成作用中的有关线索,探索应用VEGF-C基因治疗某些淋巴管形成缺陷性疾病和抑制肿瘤的淋巴管转移的新方法,本实验利用大鼠后肢环形切除部分皮肤并清扫深部淋巴管和淋巴结构建大鼠继发性淋巴水肿模型,并在水肿区局部皮下注射编码有VEGF-C基因的裸露质粒(pcDNA3.1/VEGF-C),通过MRI,超声、HE染色、免疫细胞化学等技术研究pcDNA3.1/VEGF-C是否可以促进淋巴管增生并且从解剖,功能和病理上改善淋巴水肿。
根据VEGFs家族的特性,近两年来分别有波兰,日本等学者分别用VEGF-A,VEGF-C等VEGF家族成员从胚胎干细胞中诱导出脉管母细胞表型的细胞,随后这些细胞分化并表达淋巴管内皮细胞特异性标记物(Prox-1,LYVE-1),并在基质明胶或者细胞外基质上,可形成管状结构,为淋巴水肿的基因治疗开启了一条新的思路。
骨髓基质干细胞是一类可进行自我复制和更新的细胞,在不同的理化环境和细胞因子的诱导下能够跨胚层向骨、软骨、脂肪、神经、肌肉等多种谱系分化。与胚胎干细胞相比,这种干细胞有许多优点:易于从自身取材,无免疫排斥反应之忧,涉及较少伦理问题;体外易于扩增、易分离、以及体外操作简便,因此,在组织器官缺损性疾病,组织器官退行性疾病,遗传缺陷性疾病等多方面有重要的应用前景。但是,到目前为止,骨髓基质干细胞在继发性淋巴水肿的治疗方面,甚至在干细胞向淋巴管内皮细胞诱导方面尚处于起始阶段,为了获取相关线索,探索应用VEGFs家族体外诱导骨髓基质干细胞向淋巴管内皮细胞分化的方法研究,我们利用VEGF-A,VEGF-C和EGF-A/VEGF-C联合用药在内皮细胞条件培养基中诱导骨髓基质干细胞,观察其向淋巴管内皮细胞分化的可能性,寻找VEGFs基因诱导骨髓基质干细胞向淋巴管内皮细胞分化的方法研究,为骨髓基质干细胞治疗继发性淋巴水肿提供新思路和实验依据。
目的:
1、本课题旨在探讨VEGF-C基因真核表达载体对大鼠继发性淋巴水肿模型的治疗作用及对淋巴管新生的作用,
2、寻找VEGFs基因诱导骨髓基质干细胞向淋巴管内皮细胞分化的方法研究,为骨髓基质干细胞治疗继发性淋巴水肿提供新的思路和实验依据。
研究方法:
1、继发性淋巴水肿模型的制作,将VEGF-C真核表达载体pcDNA3.1-VEGF-C注射到模型大鼠手术处的皮下组织,用核磁共振,B超,光镜以及免疫荧光等方法检测,观察VEGF-C基因对继发性淋巴水肿的治疗作用,及对淋巴管新生的作用。
2、常规分离,纯化,培养并鉴定大鼠骨髓基质干细胞:
3、取三代骨髓基质干细胞分别在VEGF-A,VEGF-C及VEGF-A/VEGF-C及条件培养基中诱导分化,于第10天,用光镜,免疫荧光,RT-PCR及Western Blot做血管内皮细胞特异性标记物CD3,CD34和淋巴管内皮细胞特异性标记物LYVE-1、Prox-1四种标志物鉴定,观察干细胞向淋巴管内皮细胞的诱导情况。
4、制备鼠尾胶原凝胶,将骨髓基质干细胞来源的淋巴管内皮细胞种植于预先制备好的胶原凝胶基质表面,观察干细胞来源的淋巴管内皮细胞形成管状结构的能力。
结果:
1、成功构建大鼠继发性淋巴水肿模型,将VEGF-C真核表达载体pcDNA3.1-VEGF-C注射到模型大鼠手术处的皮下组织,核磁共振,B超,光镜以及免疫荧光等方法检测,发现VEGF-C基因治疗组继发性淋巴水肿消退较对照组明显(P＜0.05),并在模型鼠忠处皮下发现大量新生淋巴管。
2、贴壁培养法成功培养SD雄性大鼠rMSC,通过流式细胞仪检测CD29,CD90阳性,CD34,CD45阴性证实;骨髓基质干细胞在条件培养基诱导培养10天后免疫荧光,PT-PCR及Western Blot检测发现:与对照组相比,VEGF-A,VEGF-C及VEGF-A/VEGF-C组淋巴管内皮细胞标志物LYVE-1及Prox-1均为阳性,且血管内皮细胞标志物CD31,CD34表达为阴性。
3、各组骨髓基质干细胞来源的淋巴管内皮细胞在三维培养中均无明显的管状结构形成。
结论:
1、VEGF-C基因对模型大鼠继发性淋巴水肿有一定的治疗效果,并能促进模型鼠患处皮下组织大量淋巴管新生。
2、VEGF-A,VEGF-C及VEGF-A/VEGF-C在一定的条件培养基中均能诱导骨髓基质干细胞向淋巴管内皮细胞分化,且不表达血管内皮细胞特异性标志物:但目前三维培养并无明显的管状结构形成。
创新性:
1、采用VEGF-C真核表达载体pcDNA3.1-VEGF-C探讨VEGF-C基因对模型大鼠继发性淋巴水肿的治疗作用及对淋巴管新生的作用;并结合B超,MRI等先进方法结合血管内皮细胞特异性标志物CD34及淋巴管内皮细胞特异性标志物LYVE-1对淋巴水肿的治疗效果进行检测;
2、首次采用VEGF-A,VEGF-C及VEGF-A/VEGF-C基因在体外成功诱导大鼠骨
Lymphedema is a problem of tissue fluid imbalance often due to defects in lymphatic uptake and/or transport.Primary lymphedema results from developmental defects of the lymphatic system with fewer vessels leading to insufficiencies in transport,whereas the more common secondary lymphedema arises as a consequence of surgical,malignant,inflammatory,or traumatic disruption of the lymphatics. Although secondary lymphedema is a common clinical condition,treatment for this disabling condition remains limited and largely ineffective.The rebuild of circulatory structures is a good choice to treat lymphedema,but the way how to rebuild lymphatic vessels effectively is still under study.
Recent molecular studies have begun to elucidate the basis for lymphangiogenesis which has been shown to be stimulated by various cytokines, including those in the vascular endothelial growth factor(VEGF) family:VEGF, VEGF-B,VEGF-C,VEGF-D,Orfvirus-encoded VEGF-E,and the placenta growth factor.These ligands bind to VEGF receptors(VEGFR)-1,VEGFR-2,and VEGFR-3 with partially overlapping receptor specificities.In traditionally,the prototype VEGF binds VEGF receptor(VEGFR)-1 and VEGFR-2 and is angiogenic,whereas VEGF-C, which binds to VEGFR-2 and VEGFR-3,is either angiogenic or lymphangiogenic in different assays,and the affinity of VEGF-C toward their receptors is regulated by proteolytic processing.The affinity of themature,proteolytically processed form of VEGF-C is 40 times higher for VEGFR-3 than for VEGFR-2.Furthermore,in adults VEGFR-3 is largely absent from blood vessel endothelia and remains predominantly expressed in the lymphatic endothelium.Targeted gene inactivation and transgene approaches in mice have also revealed critical roles for VEGF-C in lymphatic vessel function Adenoviral expression of VEGF-C can induce lymphangiogenesis in the skin of normal mice.
In order to resolve the questions about lymphangiogenic specificity of VEGF family in lymphedema,the scientists in Japan and Poland found that Embryonic Stem Cells treating with VEGF-A and VEGF-C individually promote lymphatic endothelial cell formation in vitro and enhance formation of lymphatic vessel structures OP9 culture condition or 3-dimensional collagen matrix.It is powerful new in vitro tool to dissect the molecular mechanisms that treat lymphedema and control lymphatic vessel formation.
Bone marrow stromal cells(MSCs),also known as mesenchymal stem cells or colony-forming units(CFU) fibroblastic,are nonhematopoietic multipotent stem-like cells that adhere to culture dishes.They are capable of clonal expansion in culture, MSCs share characteristics with other multipotent stem cells such as neural stem cells, hematopoietic stem cells because they possess the ability to self-renew and can differentiate not only into osteoblasts,chondrocytes,neurons,and skeletal muscle cells but also into vascular endothelial cells and cardiomyocytes,it has been became a kinds of ideal cell in tissue and cell repair for its merits as followed:
1.Bone marrow is an altenrative source of stem cells which are well suited for clinical application because they are easily obtained from patients and because autologous transplantation,which obviates immunologicin compatibilities is possible.
2.Of the various p rogenitorc eUsth ate xistw ithinb onem arrow,m esenchymal stem cells(MSC) are particularly attractive for clinical use because they are easily isolated,can be expanded in culture,and can be genetically manipulated using currently available molecular techniques.
3.MSCs are adult stem cells,has no ethics questions.
Objectives:
1.In order to resolve the questions about lymphangiogenic specificity of VEGF-C in lymphedema,We investigated the efficacy of local transfer of naked plasmid DNA encoding human VEGF-C(pcDNA3.1-VEGF-C) on a rat model of hindlimb lymphedema by following changes in lymphedema volume using water displacement volumetry,magnetic resonance imaging (MRI) and B ultrasound techniques.We additionally examined lymphangiogenesis using histological and immunohistochemical examinations.
2.Although many researches have demonstrated that bone marrow-derived mesenchymal stern cells(MSCs) have the potential to differentiate into mesenchymal tissues like osteocytes,chondroeytes,and adipocytes in vivo and in vitro,little information is available regarding its potential to differentiate into lymphatic endothelial cell.Thus,we investigated the differentiation of MSCs into cells of the lymphatic endothelial lineage,and investigated its bionomics by culture bone marrow stem cells on matrige with the presence of endothelial growth supplements,
Methods:
1、We produced a surgical model of secondary lymphedema in the rat hindlimb and treated with local intradermal VEGF-C(pcDNA3.1-VEGF-C) transfection to investigate the efficacy of gene transfer.Magnetic resonance imaging(MRI),B ultrasound,and water displacement volumetry demonstrated a change of lymphedema in therapy group as compared to controls.Histological and immunofluorescent studies demonstrated the numbers of newly formed lymphatic vessels in therapy group.Our results indicate that VEGF-C gene therapy has produced new lymphatic vessels.
2、Rat MSCs were isolated from bone marrow aspirate of Sprague-Dawley rats as previously described,and flow cytometry to detect the surface markers: CD29,CD90,CD34 and CD45.
3、Purified MSCs were then plated onto dishes at cell density of 1 to 1.5×10~4 cells/cm~2 in the presence of VEGF(20 ng/mL) and / or VEGF-C(50 ng/mL) cultured in differentiation medium for 4 or 7 days to media containing 2% FBS.Thenexamined CD34,CD31,Prox-1 and LYVE-1 by immunocytochemistry,RT-PCR,Western Blot..
4、Prepares collagen gel on the ice box and then put into37℃incubator. Inoculate the cells with good growth condition on the surface of the collagen gel.Then observe the growth of cultured cells by inverted phase contrast microscope.
Results:
1、The rat model got typical secondary lymphedema after operation, and one week after therapy,magnetic resonance imaging(MRI)(P<0.05),B ultrasound(P<0.05),and water displacement volumetry(P<0.05) demonstrated a reduction of lymphedema in therapy group as compared to controls.Histological and immunofluorescent studies demonstrated numerous newly formed lymphatic vessels in therapy group.
2、Rat MSCs were isolated from bone marrow aspirate of Sprague-Dawley rats as previously described,and examination demonstrated be positive for CD29 and CD90 surface markers and negative for CD34 and CD45 by f low cytometry.
5、Purified MSCs were then plated onto dishes in the presence of VEGF-A and /or VEGF-C cultured in differentiation medium for 10 days to media containing 2%FBS.The immunocytochemistry,RT-PCR,Western Blot demonstrated that compared to control group,the groups of VEGF-A, VEGF-C and VEGF-A +VEGF-C express Prox-1 and LYVE-1 but not CD34 or CD31.
6、Lymphatic endothelial cells induced from MSCs can not grow with tubiform structure in collagen gel.
Conclusions:
1、Our results indicate that VEGF-C gene therapy has produced new lymphatic vessels which may have improved functional lymphatic drainage to reduce lymphedema volume in our model.
2、In differentiation medium,MSCs treating with VEGF-A,VEGF-C and VEGF-A + VEGF-C individually promote lymphatic endothelial cell formation in vitro,and express the marks of Prox-1 and LYVE-1,but cannot grow with tubiform structure in collagen gel
Bring New Ideas:
1、We investigated the efficacy of local transfer of naked plasmid DNA encoding human VEGF-C(pcDNA3.1-VEGF-C) on a rat model of hindlimb lymphedema by following changes in lymphedema volume using water displacement volumetry,magnetic resonance imaging(MRI) and B ultrasound techniques.
2、Induced marrow stromal stem cells to lymphatic endotheliai cell with with VEGF-A,VEGF-C and VEGF-A + VEGF-C individually and detected by Immunocytochemistry,PT-PCR,Western Blot et al.
引文
1.Adams J,Carder PJ,Downey S,Forbes MA,MacLennan K,Allgar V,Kaufman S,Hallam S,Bicknell R,Walker JJ,Cairnduff F,Selby PJ,Perren TJ,Lansdown M,Banks RE.Vascular Endothelial Growth Factor(VEGF) in Breast Cancer:Comparison of Plasma,Serum,and Tissue VEGF and Microvessel Density and Effects of Tamoxifen.Cancer Res.2000;60(11):2898-2905.
2.Basile DP,Fredrich K,Chelladurai B,Leonard EC,Parrish AR.Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1,a novel VEGF inhibitor.Am J Physiol Renal Physiol.2008;294(4):F928-936.
3.Cao R,Eriksson A,Kubo H,Alitalo K,Cao Y,Thyberg J.Comparative Evaluation of FGF-2-,VEGF-A-,and VEGF-C-Induced Angiogenesis,Lymphangiogenesis,Vascular Fenestrations,and Permeability.Circ.Res.2004;94(5):664-670.
4.Clark D,Smith S,Licence D,Evans A,Charnock-Jones D.Comparison of expression patterns for placenta growth factor,vascular endothelial growth factor(VEGF),VEGF-B and VEGF-C in the human placenta throughout gestation.J.Endocrinol.1998;159(3):459-467.
5.Haiko P,Makinen T,Keskitalo S,Taipale J,Karkkainen MJ,Baldwin ME,Stacker SA,Achen MG,Alitalo K.Deletion of Vascular Endothelial Growth Factor C(VEGF-C) and VEGF-D Is Not Equivalent to VEGF Receptor 3Deletion in Mouse Embryos.Mol.Cell.Biol.2008;28(15):4843-4850.
6.Jia H,Bagherzadeh A,Bicknell R,Duchen MR,Liu D,Zachary I.Vascular Endothelial Growth Factor(VEGF)-D and VEGF-A Differentially Regulate KDR-mediated Signaling and Biological Function in Vascular Endothelial Cells.J.Biol.Chem.2004;279(34):36148-36157.
7.Mac Gabhann F,Popel AS.Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1:a computational model.Am J Physiol Heart Circ Physiol.2005;288(6):H2851-2860.
8.Roy H,Bhardwaj S,Babu M,Kokina I,Uotila S,Ahtialansaari T,Laitinen T,Hakumaki J,Laakso M,Herzig K-H,Yla-Herttuala S.VEGF-A,VEGF-D,VEGF receptor-I,VEGF receptor-2,NF-{kappa}B,and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits.FASEB J.2006;20(12):2159-2161.
9.Tille J-C,Wood J,Mandriota SJ,Schnell C,Ferrari S,Mestan J,Zhu Z,Witte L,Pepper MS.Vascular Endothelial Growth Factor(VEGF) Receptor-2Antagonists Inhibit VEGF- and Basic Fibroblast Growth Factor-Induced Angiogenesis in Vivo and in Vitro.J.Pharmacol.Exp.Ther 2001;299(3):1073-1085.
10.Tsuzuki Y,Fukumura D,Oosthuyse B,Koike C,Carmeliet P,Jain RK.Vascular Endothelial Growth Factor(VEGF) Modulation by Targeting Hypoxia-inducible Factor-1{{alpha}} {->} Hypoxia Response Element {->} VEGF Cascade Differentially Regulates Vascular Response and Growth Rate in Tumors.Cancer Res.2000;60(22):6248-6252.
11.Witzenbichler B,Asahara T,Murohara T,Silver M,Spyridopoulos I,Magnet M,Principe N,Kearney M,Hu J-S,Isner JM.Vascular Endothelial Growth Factor-C(VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia.Am.J.Pathol.1998;153(2):381-394.
12.Arbiser JL,Larsson H,Claesson-Welsh L,Bai X,LaMontagne K,Weiss SW,Soker S,Flynn E,Brown LF.Overexpression of VEGF 121 in Immortalized Endothelial Cells Causes Conversion to Slowly Growing Angiosarcoma and High Level Expression of the VEGF Receptors VEGFR-1 and VEGFR-2 in Vivo.Am.J.Pathol.2000;156(4):1469-1476.
13.Gluzman-Poltorak Z,Cohen T,Herzog Y,,Neufeld G.Neuropilin-2 is a receptor for the vascular endothelial growth factor(VEGF) forms VEGF-145 and VEGF-165.J.Biol.Chem.2000;275(38):29922-.
14.Hiratsuka S,Kataoka Y,Nakao K,Nakamura K,Morikawa S,Tanaka S,Katsuki M,Maru Y,Shibuya M.Vascular Endothelial Growth Factor A (VEGF-A) Is Involved in Guidance of VEGF Receptor-Positive Cells to the Anterior Portion of Early Embryos.Mol.Cell.Biol.2005;25(1):355-363.
15.Kawamura H,Li X,Harper SJ,Bates DO,Claesson-Welsh L.Vascular Endothelial Growth Factor(VEGF)-A165b Is a Weak In vitro Agonist for VEGF Receptor-2 Due to Lack of Coreceptor Binding and Deficient Regulation of Kinase Activity.Cancer Res.2008;68(12):4683-4692.
16.Gluzman-Poltorak Z,Cohen T,Herzog Y,Neufeld G.Neuropilin-2 and Neuropilin-1 Are Receptors for the 165-Amino Acid Form of Vascular Endothelial Growth Factor(VEGF) and of Placenta Growth Factor-2,but Only Neuropilin-2 Functions as a Receptor for the 145-Amino Acid Form of VEGF.J.Biol.Chem.2000;275(24):18040-18045.
17.Neagoe P-E,Lemieux C,Sirois MG.Vascular Endothelial Growth Factor (VEGF)-A165-induced Prostacyclin Synthesis Requires the Activation of VEGF Receptor-1 and -2 Heterodimer.J.Biol.Chem.2005;280(11):9904-9912.
18.Tabernero J.The Role of VEGF and EGFR Inhibition:Implications for Combining Anti-VEGF and Anti-EGFR Agents.Mol.Cancer Res.2007;5(3):203-220.
19.Piossek C,Schneider-Mergener J,Schirner M,Vakalopoulou E,Germeroth L,Thierauch K-H.Vascular Endothelial Growth Factor(VEGF) Receptor Ⅱ-derived Peptides Inhibit VEGF.J.Biol.Chem.1999;274(9):5612-5619.
20.Shen J,Yang X,Xiao W-H,Hackett SF,Sato Y,Campochiaro PA.Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization.FASEB J.2006:05-5046fje.
21.Vajkoczy P,Thurnher A,Hirth KP,Schilling L,Schmiedek P,Ullrich A,Menger MD.Measuring VEGF-Flk-1 Activity and Consequences of VEGF-Flk-1Targeting In Vivo Using Intravital Microscopy:Clinical Applications.Oncologist.2000;5(90001):16-19.
22.Benjamin LE,Keshet E.Conditional switching of vascular endothelial growth factor(VEGF) expression in tumors:Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF 爓ithdrawal.PNAS.1997;94(16):8761-8766.
23.Hormbrey E,Han C,Roberts A,McGrouther DA,Harris AL.The Relationship of Human Wound Vascular Endothelial Growth Factor(VEGF) After Breast Cancer Surgery to Circulating VEGF and Angiogenesis.Clin.Cancer Res.2003;9(12):4332-4339.
24.Poesen K,Lambrechts D,Van Damme P,Dhondt J,Bender F,Frank N,Bogaert E,Claes B,Heylen L,Verheyen A,Raes K,Tjwa M,Eriksson U,Shibuya M,Nuydens R,Van Den Bosch L,Meert T,D'Hooge R,Sendtner M,Robberecht W,Carmeliet P.Novel Role for Vascular Endothelial Growth Factor(VEGF) Receptor-I and Its Ligand VEGF-B in Motor Neuron Degeneration.J.Neurosci.2008;28(42):10451-10459.
25.Pradeep CR,Sunila ES,Kuttan G.Expression of Vascular Endothelial Growth Factor(VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies.Integr Cancer Ther.2005;4(4):315-321.
26.Siemeister G,Schirner M,Reusch P,Barleon B,Marme D,Martiny-Baron G.An antagonistic vascular endothelial growth factor(VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.PNAS.1998;95(8):4625-4629.
27.Moffat BA,Chen M,Kariaapper MST,Hamstra DA,Hall DE,Stojanovska J,Johnson TD,Blaivas M,Kumar M,Chenevert TL,Rehemtulla A,Ross BD.Inhibition of Vascular Endothelial Growth Factor(VEGF)-A Causes a Paradoxical Increase in Tumor Blood Flow and Up-Regulation of VEGF-D.Clin.Cancer Res.2006;12(5):1525-1532.
28.Molskness TA,Stouffer RL,Burry KA,Gorrill MJ,Lee DM,Patton PE.Circulating levels of free and total vascular endothelial growth factor (VEGF)-A,soluble VEGF receptors-1 and-2,and angiogenin during ovarian stimulation in non-human primates and women.Hum.Reprod.2004;19(4):822-830.
29.de Boer RA,Siebelink H-MJ,Tio RA,Boomsma F,van Veldhuisen DJ.Carvedilol increases plasma vascular endothelial growth factor(VEGF) in patients with chronic heart failure.Eur J Heart Fail.2001;3(3):331-333.
30.Tio RA,Tan ES,Jessurun GAJ,Veeger N,Jager PL,Slart RHJA,de Jong RM,Pruim J,Hospers GAP,,Willemsen ATM,de Jongste MJL,van Boven AJ,van Veldhuisen DJ,Zijlstra F.PET for Evaluation of Differential Myocardial Perfusion Dynamics After VEGF Gene Therapy and Laser Therapy in End-Stage Coronary Artery Disease.J.Nucl.Med.2004;45(9):1437-1443.
31.Kazi AA,Lee WS,Wagner E,Becker PM.VEGF,fetal liver kinase-1,and permeability increase during unilateral lung ischemia.Am J Physiol Lung Cell Mol Physiol.2000;279(3):L460-467.
32.Lee RJ,Springer ML,Blanco-Bose WE,Shaw R,Ursell PC,Blau HM.VEGF Gene Delivery to Myocardium:Deleterious Effects of Unregulated Expression. Circulation.2000;102(8):898-901.
33.Liang W-C,Wu X,Peale FV,Lee CV,Meng YG,Gutierrez J,Fu L,Malik AK,Gerber H-P,Ferrara N,Fuh G.Cross-species Vascular Endothelial Growth Factor(VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF.J.Biol.Chem.2006;281(2):951-961.
34.Gillespie MN,Killilea DW,Solomon M,Babal P,LeDoux SP,Wilson GL.Hypoxia Causes Oxidant Lesions in the Rat Pulmonary Artery Smooth Muscle Cell VEGF Gene:Potential Link to VEGF mRNA Expression.Chest.1998;114(1_Supplement):45S-.
35.Banga J.[Therapeutic angiogenesis through intramuscular injection of the gene for vascular endothelial growth factor(VEGF)].Ned Tijdschr Geneeskd.2000;144(3):113-116.
36.Das S,Chakraborty I,Wang J,Dey S,Hoffman L.Expression of vascular endothelial growth factor(VEGF) and VEGF- receptor messenger ribonucleic acids in the peri-implantation rabbit uterus.Biol Reprod.1997;56(6):1390-1399.
37.Paavonen K,Horelli-Kuitunen N,Chilov D,Kukk E,Pennanen S,Kallioniemi O-P,Pajusola K,Olofsson B,Eriksson U,Joukov V,Palotie A,Alitalo K.Novel Human Vascular Endothelial Growth Factor Genes VEGF-B and VEGF-C Localize to Chromosomes 11q13 and 4q34,Respectively.Circulation.1996;93(6):1079-1082.
38.Malik AK,Baldwin ME,Peale F,Fuh G,Liang W-C,Lowman H,Meng G,Ferrara N,Gerber H-P.Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice.Blood.2006;107(2):550-557.
39.Park J,Keller G,Ferrara N.The vascular endothelial growth factor(VEGF)isoforms:differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.Mol.Biol.Cell.1993;4(12):1317-1326.
40.Olofsson B,Korpelainen E,Pepper MS,Mandriota SJ,Aase K,Kumar V,Gunji Y,Jeltsch MM,Shibuya M,Alitalo K,Eriksson U.Vascular endothelial growth factor B(VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells.PNAS.1998;95(20):11709-11714.
41.Yoon Y-s,Losordo DW.All in the Family:VEGF-B Joins the Ranks of Proangiogenic Cytokines.Circ.Res.2003;93(2):87-90.
42.Claesson-Welsh L.VEGF-B Taken to Our Hearts:Specific Effect of VEGF-B in Myocardial Ischemia.Arterioscler.Thromb.Vasc.Biol.2008;28(9):1575-1576.
43.Salven P,Lymboussaki A,Heikkila P,Jaaskela-Saari H,Enholm B,Aase K,von Euler G,Eriksson U,Alitalo K,Joensuu H.Vascular Endothelial Growth Factors VEGF-B and VEGF-C Are Expressed in Human Tumors.Am.J.Pathol.1998;153(1):103-108.
44.Olofsson B,Pajusola K,vonEuler G,Chilov D,Alitalo K,Eriksson U. Genomic Organization of the Mouse and Human Genes for Vascular Endothelial Growth Factor B(VEGF-B) and Characterization of a Second Splice Isoform.J.Biol.Chem.1996;271(32):19310-19317.
45.Joukov V,Pajusola K,Kaipainen A,Chilov D,Lahtinen L Kukk E,Saksela O,Kalkkinen N,Alitalo K.A novel vascular endothelial growth factor,VEGF-C,is a ligand for the Flt4(VEGFR-3) and KDR(VEGFR-2) receptor tyrosine kinases.EMBO J.1996;15(2):290-298.
46.Joukov V,Kaipainen A,Jeltsch M,Pajusola K,Olofsson B,Kumar V,Eriksson U,Alitalo K.Vascular endothelial growth factors VEGF-B and VEGF-C.J Cell Physiol.1997;173(2):211-215.
47.Joukov V,Pajusola K,Kaipainen A,Chilov D,Lahtinen L Kukk E,Saksela O,Kalkkinen N,Alitalo K.A novel vascular endothelial growth factor,VEGF-C,is a ligand for the Flt4(VEGFR-3) and KDR(VEGFR-2) receptor tyrosine kinases.EMBO J.1996;15(7):1751.
48.Wartiovaara U,Salven P,Mikkola H,Lassila R,Kaukonen J,Joukov V,Orpana A,Ristimaki A,Heikinheimo M,Joensuu H,Alitalo K,Palotie A.Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.Thromb Haemost.1998;80(1):171-175.
49.Lymboussaki A,Olofsson B,Eriksson U,Alitalo K.Vascular Endothelial Growth Factor(VEGF) and VEGF-C Show Overlapping Binding Sites in Embryonic Endothelia and Distinct Sites in Differentiated Adult Endothelia.Circ.Res.1999;85(11):992-999.
50.Kadambi A,Mouta Carreira C,Yun C-o,Padera TP,Dolmans DEJGJ,Carmeliet P,Fukumura D,Jain RK.Vascular Endothelial Growth Factor (VEGF)-C Differentially Affects Tumor Vascular Function and Leukocyte Recruitment:Role of VEGF-Receptor 2 and Host VEGF-A.Cancer Res.2001;61(6):2404-2408.
51.Oh H,Takagi H,Otani A,Koyama S,Kemmochi S,Uemura A,Honda Y.Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF):A mechanism contributing to VEGF-induced angiogenesis.PNAS.2002;99(1):383-388.
52.Kukk E,Lymboussaki A,Taira S,Kaipainen A,Jeltsch M,Joukov V,Alitalo K.VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.Development.1996;122(12):3829-3837.
53.Zhao B,Ma A,Cai J,Boulton M.VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells.Br.J.Ophthalmol.2006;90(8):1052-1059.
54.Achen MG,Jeltsch M,Kukk E,Makinen T,Vitali A,Wilks AF,Alitalo K,Stacker SA.Vascular endothelial growth factor D(VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2?Flk1) and VEGF receptor??Flt4).PNAS.1998;95(2):548-553.
55.Karpanen T,Heckman CA,Keskitalo S,Jeltsch M,Ollila H,Neufeld G,Tamagnone L,Alitalo K.Functional interaction of VEGF-C and VEGF-D with neuropilin receptors.FASEB J.2006;20(9):1462-1472.
56.Persaud K,Tille J-C,Liu M,Zhu Z,Jimenez X,Pereira DS,Miao H-Q,Brennan LA,Witte L,Pepper MS,Pytowski B.Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C.J.Cell Sci.2004;117(13):2745-2756.
57.Gomez R,Gonzalez-Izquierdo M,Zimmermann RC,Novella-Maestre E,Alonso-Muriel L Sanchez-Criado J,Remohi J,Simon C,Pellicer A.Low-Dose Dopamine Agonist Administration Blocks Vascular Endothelial Growth Factor (VEGF)-Mediated Vascular Hyperpermeability without Altering VEGF Receptor 2-Dependent Luteal Angiogenesis in a Rat Ovarian Hyperstimulation Model.Endocrinology.2006;147(11):5400-5411.
58.McColl BK,Baldwin ME,Roufail S,Freeman C,Moritz RL,Simpson RJ,Alitalo K,Stacker SA,Achen MG.Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D.J.Exp.Med.2003;198(6):863-868.
59.He Y,Smith SK,Day KA,Clark DE,Licence DR,Charnock-Jones DS.Alternative Splicing of Vascular Endothelial Growth Factor(VEGF)-R1(FLT-1) pre-mRNA Is Important for the Regulation of VEGF Activity.Mol.Endocrinol.1999;13(4):537-545.
60.De Bandt M,Ben Mahdi MH,Ollivier V,Grossin M,Dupuis M,Gaudry M,Bohlen P,Lipson KE,Rice A,Wu Y,Gougerot-Pocidalo M-A,Pasquier C.Blockade of Vascular Endothelial Growth Factor Receptor I(VEGF-RI),but not VEGF-RII,Suppresses Joint Destruction in the K/BxN Model of Rheumatoid Arthritis.J.Immunol.2003;171(9):4853-4859.
61.Onofri C,Theodoropoulou M,Losa M,Uhl E,Lange M,Arzt E,Stalla GK,Renner U.Localization of vascular endothelial growth factor(VEGF)receptors in normal and adenomatous pituitaries:detection of a non-endothelial function of VEGF in pituitary tumours.J.Endocrinol.2006;191(1):249-261.
62.Holash J,Davis S,Papadopoulos N,Croll SD,Ho L,Russell M,Boland P,Leidich R,Hylton D,Burova E,Ioffe E,Huang T,Radziejewski C,Bailey K,Fandl JP,Daly T,Wiegand SJ,,Yancopoulos GD,Rudge JS.VEGF-Trap:A VEGF blocker with potent antitumor effects.PNAS.2002;99(17):11393-11398.
63.Pasquali D,Rossi V,Staibano S,De Rosa G,Chieffi P,Prezioso D,Mirone V,Mascolo M,Tramontano D,Bellastella A,Sinisi AA.The Endocrine-Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF)/Prokineticin 1 and 2 and Receptor Expression in Human Prostate:Up-Regulation of EG-VEGF/Prokineticin 1 with Malignancy.Endocrinology.2006;147(9):4245-4251.
64.Yamaji-Kegan K,Su Q,Angelini DJ,Champion HC,Johns RA.Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2.Am J Physiol Lung Cell Mol Physiol.2006;291(6):L1159-1168.
65.Brekken RA,Overholser JP,Stastny VA,Waltenberger J,Minna JD,Thorpe PE.Selective Inhibition of Vascular Endothelial Growth Factor(VEGF) Receptor 2(KDR/FIk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice.Cancer Res.2000;60(18):5117-5124.
66.Schmidt-Erfurth U,Schlotzer-Schrehard U,Cursiefen C,Michels S,Beckendorf A,Naumann GOH.Influence of Photodynamic Therapy on Expression of Vascular Endothelial Growth Factor(VEGF),VEGF Receptor 3,and Pigment Epithelium-Derived Factor.Invest.Ophthalmol.Vis.Sci.2003;44(10):4473-4480.
67.Zygalaki E,Tsaroucha EG,Kaklamanis L,Lianidou ES.Quantitative Real-Time Reverse Transcription PCR Study of the Expression of Vascular Endothelial Growth Factor(VEGF) Splice Variants and VEGF Receptors (VEGFR-1 and VEGFR-2) in Non Small Cell Lung Cancer.Clin.Chem.2007;53(8):1433-1439.
68.Hinrichs CS,Watroba NL,Rezaishiraz H,Giese W,Hurd T,Fassl KA,Edge SB.Lymphedema Secondary to Postmastectomy Radiation:Incidence and Risk Factors.Ann.Surg.Oncol.2004;11(6):573-580.
69.Lawenda BD,Mondry TE,Johnstone PAS.Lymphedema Lymphedema:A primer on the identification and management of a chronic condition in oncologic treatment.CA Cancer J Clin.2009;59(1):25-26.
70.Thomas-MacLean R,Miedema B,Tatemichi,SR.Breast cancer-related lymphedema:women's experiences with an underestimated condition.Can Fam Physician.2005;51(2):246-247.
71.Holmes LB,Fields JP,Zabriskie JB.Hereditary Late-Onset Lymphedema.Pediatrics.1978;61(4):575-579.
72.Wing PL,Harris SR,Ciccone CD.More reader comments on "Can a comprehensive lymphedema management program decrease limb size and reduce the incidence of infection in a woman with postmastectomy lymphedema? ".Physical Therapy.2002;82(9):923-924.
73.Mortimer PS.Therapy Approaches for Lymphedema.Angiology.1997;48(1):87-91.
74.Liu Y,Fang Y,Dong P,Gao J,Liu R,Tian H,Ding Z,Bi Y,Liu Z.Effect of vascular endothelial growth factor C(VEGF-C) gene transfer in rat model of secondary lymphedema.Vascul Pharmacol.2008;49(1):44-50.
75.Hu X,Jiang Z,Liu N.[Experimental studies of VEGF-C gene for the treatment of chronic obstructive lymphedema in mouse tail model].Zhonghua Zheng Xing Wai Ke Za Zhi.2008;24(3):207-211.
76.Rutkowski J,Moya M,Johannes J,Goldman J,Swartz M.Secondary lymphedema in the mouse tail:Lymphatic hyperplasia,VEGF-C upregulation,and the protective role of MMP-9.Microvasc Res.2006;72(3):161-171.
77.Fink A,Kaltenegger I,Schneider B,Fruhauf J,Jurecka W,Steiner A.Serum level of VEGF-D in patients with primary lymphedema.Lymphology.2004;37(4):185-189.
78.Jin dP,An A,Liu J,Nakamura K,Rockson S.Therapeutic Responses to Exogenous VEGF-C Administration in Experimental Lymphedema:Immunohistochemical and Molecular Characterization.Lymphat Res Biol.2009;7(1):47-57.
79.Yoon Y,Murayama T,Gravereaux E,Tkebuchava T,Silver M,Curry C,Wecker A,Kirchmair R,Hu C,Kearney M,Ashare A,Jackson D,Kubo H,Isner J,Losordo D.VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema.J Clin Invest.2003;111(5):717-725.
80.Feng D,Nagy JA,Brekken RA,Pettersson A,Manseau EJ,Pyne K,Mulligan R,Thorpe PE,Dvorak HF,Dvorak AM.Ultrastructural Localization of the Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Receptor-2(FLK-1,KDR) in Normal Mouse Kidney and in the Hyperpermeable Vessels Induced by VPF/VEGF-expressing Tumors and Adenoviral Vectors.J.Histochem.Cytochem.2000;48(4):545-556.
81.Butler DF,Malouf PJ,Batz RC,Stetson CL.Acquired Lymphedema of the Hand Due to Herpes Simplex Virus Type 2.Arch Dermatol.1999;135(9):1125-1126.
82.Patel AR,Charles CA,Ricotti CA,Romanelli P,Connelly EA.Cutaneous Tumors,Massive Lymphadenopathy,and Secondary Lymphedema in a 16-Year-Old Boy--Quiz Case.Arch Dermatol.2008;144(9):1217-f-1222.
83.Norman SA,Localio AR,Potashnik SL,Simoes Torpey HA,Kallan MJ,Weber AL,Miller LT,DeMichele A,Solin LJ.Lymphedema in Breast Cancer Survivors:Incidence,Degree,Time Course,Treatment,and Symptoms.J.Clin.Oncol.2009;27(3):390-397.
84.Hadamitzky C,Pabst R.Acquired Lymphedema:An Urgent Need for Adequate Animal Models.Cancer Res.2008;68(2):343-345.
85.Yalcin E,Dogru D,Gonc EN,Cetinkaya A,Kiper N.Yellow Nail Syndrome in an Infant Presenting with Lymphedema of the Eyelids and Pleural Effusion.Clinical Pediatrics.2004;43(6):569-572.
86.Brofman J,Hall J,Scott W,Little A.Yellow nails,lymphedema and pleural effusion.Treatment of chronic pleural effusion with pleuroperitoneal shunting.Chest.1990;97(3):743-745.
87.Szuba A,Rockson SG.Lymphedema:classification,diagnosis and therapy.Vascular Medicine.1998;3(2):145-156.
88.Burstein HJ,Chen Y-H,Parker LM,Savoie J,Younger J,Kuter L Ryan PD,Garber JE,Chen H,Campos SM,Shulman LN,Harris LN,Gelman R,Winer EP.VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy.Clin.Cancer Res.200&14(23):7871-7877.
89.Southern JF.Moscicki RA,Magro C,Dickersin GR,Fallon JT,Bloch KJ.Lymphedema,lymphocytic myocarditis,and sarcoidlike granulomatosis.Manifestations of Whipple's disease.JAMA.1989;261(10):1467-1470.
90.Hayes SC,Janda M,Cornish B,Battistutta D,Newman B.Lymphedema After Breast Cancer:Incidence,Risk Factors,and Effect on Upper Body Function.J.Clin.Oncol.2008;26(21):3536-3542.
91.Wrone DA,Tanabe KK,Cosimi AB,Gadd MA,Souba WW,Sober AJ.Lymphedema After Sentinel Lymph Node Biopsy for Cutaneous Melanoma:A Report of 5 Cases.Arch Dermatol.2000;136(4):511-514.
92.Stacker SA,Vitali A,Caesar C,Domagala T,Groenen LC,Nice E,Achen MG,Wilks AF.A Mutant Form of Vascular Endothelial Growth Factor(VEGF) That Lacks VEGF Receptor-2 Activation Retains the Ability to Induce Vascular Permeability.J.Biol.Chem.1999;274(49):34884-34892.
93.Hiltunen MO,Laitinen M,Turunen MP,Jeltsch M,Hartikainen J,Rissanen TT,Laukkanen J,Niemi M,Kossila M,Hakkinen TP,Kivela A,Enholm B,Mansukoski H,Turunen A-M,Alitalo K,Yla-Herttuala S.Intravascular Adenovirus-Mediated VEGF-C Gene Transfer Reduces Neointima Formation in Balloon-Denuded Rabbit Aorta.Circulation.2000;102(18):2262-2268.
94.Jeltsch M,Karpanen T,Strandin T,Aho K,Lankinen H,Alitalo K.Vascular Endothelial Growth Factor(VEGF)/VEGF-C Mosaic Molecules Reveal Specificity Determinants and Feature Novel Receptor Binding Patterns.J.Biol.Chem.2006;281(17):12187-12195.
95.Eichmann A,Corbel C,Jaffredo T,Breant C,Joukov V,Kumar V,Alitalo K,le Douarin N.Avian VEGF-C:cloning,embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors.Development.1998;125(4):743-752.
96.Pipes BL,Ablin RJ.Embryonic Stem Cell Co-Transplantation Revisited:Utility of Umbilical Cord Blood "Embryonic-Like" Stem Cells.Ann.Clin.Lab.Sci.2006;36(1):105-106.
97.Wang Y,Yates F.Naveiras O,Ernst P,Daley GQ.Embryonic stem cell-derived hematopoietic stem cells.PNAS.2005;102(52):19081-19086.
98.Zerhouni E.EMBRYONIC STEM CELLS:Enhanced:Stem Cell Programs.Science.2003;300(5621):911-912.
1.Adams J,Carder PJ,Downey S,Forbes MA,MacLennan K,Allgar V,Kaufman S,Hallam S,Bicknell R,Walker JJ,Caimduff F,Selby PJ,Perren TJ,Lansdown M,Banks RE.Vascular Endothelial Growth Factor(VEGF) in Breast Cancer:Comparison of Plasma,Serum,and Tissue VEGF and Microvessel Density and Effects of Tamoxifen.Cancer Res.2000;60(11):2898-2905.
2.Basile DP,Fredrich K,Chelladurai B,Leonard EC,Parrish AR.Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1,a novel VEGF inhibitor.Am J Physiol Renal Physiol.2008;294(4):F928-936.
3.Cao R,Eriksson A,Kubo H,Alitalo K,Cao Y,Thyberg J.Comparative Evaluation of FGF-2-,VEGF-A-,and VEGF-C-Induced Angiogenesis,Lymphangiogenesis,Vascular Fenestrations,and Permeability.Circ.Res.2004;94(5):664-670.
4.Clark D,Smith S,Licence D,Evans A,Charnock-Jones D.Comparison of expression patterns for placenta growth factor,vascular endothelial growth factor(VEGF),VEGF-B and VEGF-C in the human placenta throughout gestation.J.Endocrinol.1998;159(3):459-467.
5.Haiko P,Makinen T,Keskitalo S,Taipale J,Karkkainen MJ,Baldwin ME,Stacker SA,Achen MG.Alitalo K.Deletion of Vascular Endothelial Growth Factor C(VEGF-C) and VEGF-D Is Not Equivalent to VEGF Receptor 3Deletion in Mouse Embryos.Mol.Cell.Biol.2008;28(15):4843-4850.
6.Jia H,Bagherzadeh A,Bicknell R,Duchen MR,Liu D,Zachary I.Vascular Endothelial Growth Factor(VEGF)-D and VEGF-A Differentially Regulate KDR-mediated Signaling and Biological Function in Vascular Endothelial Cells.J.Biol.Chem.2004;279(34):36148-36157.
7.Mac Gabhann F,Popel AS.Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1:a computational model.Am J Physiol Heart Circ Physiol.2005;288(6):H2851-2860.
8.Roy H,Bhardwaj S,Babu M,Kokina I,Uotila S,Ahtialansaari T,Laitinen T,Hakumaki J,Laakso M,Herzig K-H,Yla-Herttuala S.VEGF-A,VEGF-D,VEGF receptor-1,VEGF receptor-2,NF-{kappa}B,and RAGE in atherosclerotic lesions of diabetic Watanabe heritable hyperlipidemic rabbits.FASEB J.2006;20(12):2159-2161.
9.Tille J-C,Wood J,Mandriota SJ,Schnell C,Ferrari S,Mestan J,Zhu Z,Witte L,Pepper MS.Vascular Endothelial Growth Factor(VEGF) Receptor-2Antagonists Inhibit VEGF- and Basic Fibroblast Growth Factor-Induced Angiogenesis in Vivo and in Vitro.J.Pharmacol.Exp.Ther.2001;299(3):1073-1085.
10.Tsuzuki Y,Fukumura D,Oosthuyse B,Koike C,Carmeliet P,Jain RK.Vascular Endothelial Growth Factor(VEGF) Modulation by Targeting Hypoxia-inducible Factor-1{{alpha}} {->} Hypoxia Response Element {->} VEGF Cascade Differentially Regulates Vascular Response and Growth Rate in Tumors.Cancer Res.2000;60(22):6248-6252.
11.Witzenbichler B,Asahara T,Murohara T,Silver M,Spyridopoulos I,Magner M,Principe N,Kearney M,Hu J-S,Isner JM.Vascular Endothelial Growth Factor-C(VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia.Am.J.Pathol.1998;153(2):381-394.
12.Arbiser JL,Larsson H,Claesson-Welsh L,Bai X,LaMontagne K,Weiss SW,Soker S,Flynn E,Brown LF.Overexpression of VEGF 121 in Immortalized Endothelial Cells Causes Conversion to Slowly Growing Angiosarcoma and High Level Expression of the VEGF Receptors VEGFR-1 and VEGFR-2 in Vivo.Am.J.Pathol.2000;156(4):1469-1476.
13.Gluzman-Poltorak Z,Cohen T,Herzog Y,Neufeld G.Neuropilin-2 is a receptor for the vascular endothelial growth factor(VEGF) forms VEGF-145and VEGF-165.J.Biol.Chem.2000;275(38):29922-.
14.Hiratsuka S,Kataoka Y,Nakao K,Nakamura K,Morikawa S,Tanaka S,Katsuki M,Maru Y,Shibuya M.Vascular Endothelial Growth Factor A (VEGF-A) Is Involved in Guidance of VEGF Receptor-Positive Cells to the Anterior Portion of Early Embryos.Mol.Cell.Biol.2005;25(1):355-363.
15.Kawamura H,Li X,Harper SJ,Bates DO,Claesson-Welsh L.Vascular Endothelial Growth Factor(VEGF)-A165b Is a Weak In vitro Agonist for VEGF Receptor-2 Due to Lack of Coreceptor Binding and Deficient Regulation of Kinase Activity.Cancer Res.2008;68(12):4683-4692.
16.Gluzman-Poltorak Z,Cohen T,Herzog Y,Neufeld G.Neuropilin-2 and Neuropilin-1 Are Receptors for the 165-Amino Acid Form of Vascular Endothelial Growth Factor(VEGF) and of Placenta Growth Factor-2,but Only Neuropilin-2 Functions as a Receptor for the 145-Amino Acid Form of VEGF.J.Biol.Chem.2000;275(24):18040-18045.
17.Neagoe P-E,Lemieux C,Sirois MG.Vascular Endothelial Growth Factor (VEGF)-A165-induced Prostacyclin Synthesis Requires the Activation of VEGF Receptor-1 and -2 Heterodimer.J.Biol.Chem.2005;280(11):9904-9912.
18.Tabemero J.The Role of VEGF and EGFR Inhibition:Implications for Combining Anti-VEGF and Anti-EGFR Agents.Mol.Cancer Res.2007;5(3):203-220.
19.Piossek C,Schneider-Mergener J,Schirner M,Vakalopoulou E,Germeroth L,Thierauch K-H.Vascular Endothelial Growth Factor(VEGF) Receptor Ⅱ-derived Peptides Inhibit VEGF.J.Biol.Chem.1999;274(9):5612-5619.
20.Shen J,Yang X,Xiao W-H,Hackett SF,Sato Y,Campochiaro PA.Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization.FASEB J.2006:05-5046fje.
21.Vajkoczy P,Thurnher A,Hirth KP,Schilling L,Schmiedek P,Ullrich A,Menger MD.Measuring VEGF-Flk-1 Activity and Consequences of VEGF-Flk-1 Targeting In Vivo Using Intravital Microscopy:Clinical Applications.Oncologist.2000;5(90001):16-19.
22.Benjamin LE,Keshet E.Conditional switching of vascular endothelial growth factor(VEGF) expression in tumors:Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF 爓 ithdrawal.PNAS.1997;94(16):8761-8766.
23.Hormbrey E,Han C,Roberts A,McGrouther DA,Harris AL.The Relationship of Human Wound Vascular Endothelial Growth Factor(VEGF) After Breast Cancer Surgery to Circulating VEGF and Angiogenesis.Clin.Cancer Res.2003;9(12):4332-4339.
24.Poesen K,Lambrechts D,Van Damme P,Dhondt J,Bender F,Frank N,Bogaert E,Claes B,Heylen L,Verheyen A,Raes K,Tjwa M,Eriksson U,Shibuya M,Nuydens R,Van Den Bosch L,Meert T,D'Hooge R,Sendtner M,Robberecht W,Carmeliet P.Novel Role for Vascular Endothelial Growth Factor(VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration.J.Neurosci.2008;28(42):10451-10459.
25.Pradeep CR,Sunila ES,Kuttan G.Expression of Vascular Endothelial Growth Factor(VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies.Integr Cancer Ther.2005;4(4):315-321.
26.Siemeister G,Schirner M,Reusch P,Barleon B,Marrne D,Martiny-Baron G.An antagonistic vascular endothelial growth factor(VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells.PNAS.1998;95(8):4625-4629.
27.Moffat BA,Chen M,Kariaapper MST,Hamstra DA,Hall DE,Stojanovska J,Johnson TD,Blaivas M,Kumar M,Chenevert TL,Rehemtulla A,Ross BD.Inhibition of Vascular Endothelial Growth Factor(VEGF)-A Causes a Paradoxical Increase in Tumor Blood Flow and Up-Regulation of VEGF-D.Clin.Cancer Res.2006;12(5):1525-1532.
28.Molskness TA,Stouffer RL,Burry KA,Gorrill MJ,Lee DM,Patton PE.Circulating levels of free and total vascular endothelial growth factor (VEGF)-A,soluble VEGF receptors-1 and -2,and angiogenin during ovarian stimulation in non-human primates and women.Hum.Reprod.2004;19(4):822-830.
29.de Boer RA,Siebelink H-MJ,Tio RA,Boomsma F,van Veldhuisen DJ.Carvedilol increases plasma vascular endothelial growth factor(VEGF) in patients with chronic heart failure.Eur J Heart Fail,2001;3(3):331-333.
30.Tio RA,Tan ES,Jessurun GAJ,Veeger N,Jager PL,Slart RHJA,de Jong RM,Pruim J,Hospers GAP,Willemsen ATM,de Jongste MJL,van Boven AJ,van Veldhuisen DJ,Zijlstra F.PET for Evaluation of Differential Myocardial Perfusion Dynamics After VEGF Gene Therapy and Laser Therapy in End-Stage Coronary Artery Disease.J.Nucl.Med.2004;45(9):1437-1443.
31.Kazi AA,Lee WS,Wagner E,Becker PM.VEGF,fetal liver kinase-1,and permeability increase during unilateral lung ischemia.Am J Physiol Lung Cell Mol Physiol.2000;279(3):L460-467.
32.Lee RJ,Springer ML,Blanco-Bose WE,Shaw R,Ursell PC,Blau HM.VEGF Gene Delivery to Myocardium:Deleterious Effects of Unregulated Expression.Circulation.2000;102(8):898-901.
33.Liang W-C,Wu X,Peale FV,Lee CV,Meng YG,Gutierrez J,Fu L,Malik AK,Gerber H-P,Ferrara N,Fuh G Cross-species Vascular Endothelial Growth Factor(VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGE J.Biol.Chem.2006;281(2):951-961.
34.Gillespie MN,Killilea DW,Solomon M,Babal P,LeDoux SP,Wilson GL.Hypoxia Causes Oxidant Lesions in the Rat Pulmonary Artery Smooth Muscle Cell VEGF Gene:Potential Link to VEGF mRNA Expression.Chest.1998;114(1_Supplement):45S-.
35.Banga J.[Therapeutic angiogenesis through intramuscular injection of the gene for vascular endothelial growth factor(VEGF)].Ned Tijdschr Geneeskd.2000;144(3):113-116.
36.Das S,Chakraborty I,Wang J,Dey S,Hoffman L.Expression of vascular endothelial growth factor(VEGF) and VEGF- receptor messenger ribonucleic acids in the peri-implantation rabbit uterus.Biol Reprod.1997;56(6):1390-1399.
37.Paavonen K,Horelli-Kuitunen N,Chilov D,Kukk E,Pennanen S,Kallioniemi O-P,Pajusola K,Olofsson B,Eriksson U,Joukov V,Palotie A,Alitalo K.Novel Human Vascular Endothelial Growth Factor Genes VEGF-B and VEGF-C Localize to Chromosomes 11q13 and 4q34,Respectively.Circulation.1996;93(6):1079-1082.
38.Malik AK,Baldwin ME,Peale F,Fuh G,Liang W-C,Lowman H,Meng G,Ferrara N,Gerber H-P.Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice.Blood.2006;107(2):550-557.
39.Park J,Keller G,Ferrara N.The vascular endothelial growth factor(VEGF)isoforms:differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.Mol.Biol.Cell.1993;4(12):1317-1326.
40.Olofsson B,Korpelainen E,Pepper MS,Mandriota SJ,Aase K,Kumar V,Gunji Y,Jeltsch MM,Shibuya M,Alitalo K,Eriksson U.Vascular endothelial growth factor B(VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells.PNAS.1998;95(20):11709-11714.
41.Yoon Y-s,Losordo DW.All in the Family:VEGF-B Joins the Ranks of Proangiogenic Cytokines.Circ.Res.2003;93(2):87-90.
42.Claesson-Welsh L.VEGF-B Taken to Our Hearts:Specific Effect of VEGF-B in Myocardial Ischemia.Arterioscler.Thromb.Vasc.Biol.2008;28(9):1575-1576.
43.Salven P,Lymboussaki A,Heikkila P,Jaaskela-Saari H,Enholm B,Aase K,von Euler G,Eriksson U,Alitalo K,Joensuu H.Vascular Endothelial Growth Factors VEGF-B and VEGF-C Are Expressed in Human Tumors.Am.J.Pathol.1998;153(1):103-108.
44.Olofsson B,Pajusola K,vonEuler G,Chilov D,Alitalo K,Eriksson U. Genomic Organization of the Mouse and Human Genes for Vascular Endothelial Growth Factor B(VEGF-B) and Characterization of a Second Splice Isoform.J.Biol.Chem.1996;271(32):19310-19317.
45.Joukov V,Pajusola K,Kaipainen A,Chilov D,Lahtinen I,Kukk E,Saksela O,Kalkkinen N,Alitalo K.A novel vascular endothelial growth factor,VEGF-C,is a ligand for the Flt4(VEGFR-3) and KDR(VEGFR-2) receptor tyrosine kinases.EMBO J.1996;15(2):290-298.
46.Joukov V,Kaipainen A,Jeltsch M,Pajusola K,Olofsson B,Kumar V,Eriksson U,Alitalo K.Vascular endothelial growth factors VEGF-B and VEGF-C.J Cell Physiol.1997;173(2):211-215.
47.Joukov V,Pajusola K,Kaipainen A,Chilov D,Lahtinen I,Kukk E,Saksela O,Kalkkinen N,Alitalo K.A novel vascular endothelial growth factor,VEGF-C,is a ligand for the Flt4(VEGFR-3) and KDR(VEGFR-2) receptor tyrosine kinases.EMBO J.1996;15(7):1751.
48.Wartiovaara U,Salven P,Mikkola H,Lassila R,Kaukonen J,Joukov V,Orpana A,Ristimaki A,Heikinheimo M,Joensuu H,Alitalo K,Palotie A.Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.Thromb Haemost.1998;80(1):171-175.
49.Lymboussaki A,Olofsson B,Eriksson U,Alitalo K.Vascular Endothelial Growth Factor(VEGF) and VEGF-C Show Overlapping Binding Sites in Embryonic Endothelia and Distinct Sites in Differentiated Adult Endothelia.Circ.Res.1999;85(11):992-999.
50.Kadambi A,Mouta Carreira C,Yun C-o,Padera TP,Dolmans DEJGJ,Carmeliet P,Fukumura D,Jain RK.Vascular Endothelial Growth Factor (VEGF)-C Differentially Affects Tumor Vascular Function and Leukocyte Recruitment:Role of VEGF-Receptor 2 and Host VEGF-A.Cancer Res.2001;61(6):2404-2408.
51.Oh H,Takagi H,Otani A,Koyama S,Kemmochi S,Uemura A,Honda Y.Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF):A mechanism contributing to VEGF-induced angiogenesis.PNAS.2002;99(1):383-388.
52.Kukk E,Lymboussaki A,Taira S,Kaipainen A,Jeltsch M,Joukov V,Alitalo K.VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.Development.1996;122(12):3829-3837.
53.Zhao B,Ma A,Cai J,Boulton M.VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells.Br.J.Ophthalmol.2006;90(8):1052-1059.
54.Achen MG,Jeltsch M,Kukk E,Makinen T,Vitali A,Wilks AF,Alitalo K,Stacker SA.Vascular endothelial growth factor D(VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2?Flkl) and VEGF receptor??Flt4).PNAS.1998;95(2):548-553.
55.Karpanen T,Heckman CA,Keskitalo S,Jeltsch M,Ollila H,Neufeld G,Tamagnone L,Alitalo K.Functional interaction of VEGF-C and VEGF-D with neuropilin receptors.FASEB J.2006;20(9):1462-1472.
56.Persaud K,Tille J-C,Liu M,Zhu Z,Jimenez X,Pereira DS,Miao H-Q,Brennan LA,Witte L,Pepper MS,Pytowski B.Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C.J.Cell Sci.2004;117(13):2745-2756.
57.Gomez R,Gonzalez-Izquierdo M,Zimmermann RC,Novella-Maestre E,Alonso-Muriel I,Sanchez-Criado J,Remohi J,Simon C,Pellicer A.Low-Dose Dopamine Agonist Administration Blocks Vascular Endothelial Growth Factor (VEGF)-Mediated Vascular Hyperpermeability without Altering VEGF Receptor 2-Dependent Luteal Angiogenesis in a Rat Ovarian Hyperstimulation Model.Endocrinology.2006;147(11):5400-5411.
58.McColl BK,Baldwin ME,Roufail S,Freeman C,Moritz RL,Simpson RJ,Alitalo K,Stacker SA,Achen MG.Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D.J.Exp.Med.2003;198(6):863-868.
59.He Y,Smith SK,Day KA,Clark DE,Licence DR,Charnock-Jones DS.Alternative Splicing of Vascular Endothelial Growth Factor(VEGF)-R1(FLT-1) pre-mRNA Is Important for the Regulation of VEGF Activity.Mol.Endocrinol.1999;13(4):537-545.
60.De Bandt M,Ben Mahdi MH,Ollivier V,Grossin M,Dupuis M,Gaudry M,Bohlen P,Lipson KE,Rice A,Wu Y,Gougerot-Pocidalo M-A,Pasquier C.Blockade of Vascular Endothelial Growth Factor Receptor I(VEGF-RI),but not VEGF-RII,Suppresses Joint Destruction in the K/BxN Model of Rheumatoid Arthritis.J.Immunol.2003;171(9):4853-4859.
61.Onofri C,Theodoropoulou M,Losa M,Uhl E,Lange M,Arzt E,Stalla GK,Renner U.Localization of vascular endothelial growth factor(VEGF)receptors in normal and adenomatous pituitaries:detection of a non-endothelial function of VEGF in pituitary tumours.J.Endocrinol.2006;191(1):249-261.
62.Holash J,Davis S,Papadopoulos N,Croll SD,Ho L,Russell M,Boland P,Leidich R,Hylton D,Burova E,Ioffe E,Huang T,Radziejewski C,Bailey K,Fandl JP,Daly T,Wiegand SJ,Yancopoulos GD,Rudge JS.VEGF-Trap:A VEGF blocker with potent antitumor effects.PNAS.2002;99(17):11393-11398.
63.Pasquali D,Rossi V,Staibano S,De Rosa G,Chieffi P,Prezioso D,Mirone V,Mascolo M,Tramontano D,Bellastella A,Sinisi AA.The Endocrine-Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF)/Prokineticin 1 and 2 and Receptor Expression in Human Prostate:Up-Regulation of EG-VEGF/Prokineticin 1 with Malignancy.Endocrinology.2006;147(9):4245-4251.
64.Yamaji-Kegan K,Su Q,Angelini DJ,Champion HC,Johns RA.Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2.Am J Physiol Lung Cell Mol Physiol.2006;291(6):L1159-1168.
65.Brekken RA,Overholser JP,Stastny VA,Waltenberger J,Minna JD,Thorpe PE.Selective Inhibition of Vascular Endothelial Growth Factor(VEGF)Receptor 2(KDR/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice.Cancer Res.2000;60(18):5117-5124.
66.Schmidt-Erfurth U,Schlotzer-Schrehard U,Cursiefen C,Michels S,Beckendorf A,Naumann GOH.Influence of Photodynamic Therapy on Expression of Vascular Endothelial Growth Factor(VEGF),VEGF Receptor 3,and Pigment Epithelium-Derived Factor.Invest.Ophthalmol.Vis.Sci.2003;44(10):4473-4480.
67.Zygalaki E,Tsaroucha EG,Kaklamanis L,Lianidou ES.Quantitative Real-Time Reverse Transcription PCR Study of the Expression of Vascular Endothelial Growth Factor(VEGF) Splice Variants and VEGF Receptors (VEGFR-1 and VEGFR-2) in Non Small Cell Lung Cancer.Clin.Chem.2007;53(8):1433-1439.
68.Hinrichs CS,Watroba NL,Rezaishiraz H,Giese W,Hurd T,Fassl KA,Edge SB.Lymphedema Secondary to Postmastectomy Radiation:Incidence and Risk Factors.Ann.Surg.Oncol.2004;11(6):573-580.
69.Lawenda BD,Mondry TE,Johnstone PAS.Lymphedema Lymphedema:A primer on the identification and management of a chronic condition in oncologic treatment.CA Cancer J Clin.2009;59(1):25-26.
70.Thomas-MacLean R,Miedema B,Tatemichi,SR.Breast cancer-related lymphedema:women's experiences with an underestimated condition.Can Fam Physician.2005;51(2):246-247.
71.Holmes LB,Fields JP,Zabriskie JB.Hereditary Late-Onset Lymphedema.Pediatrics.1978;61(4):575-579.
72.Wing PL,Harris SR,Ciccone CD.More reader comments on "Can a comprehensive lymphedema management program decrease limb size and reduce the incidence of infection in a woman with postmastectomy lymphedema?".Physical Therapy.2002;82(9):923-924.
73.Mortimer PS.Therapy Approaches for Lymphedema.Angiology.1997;48(1):87-91.
74.Liu Y,Fang Y,Dong P,Gao J,Liu R,Tian H,Ding Z,Bi Y,Liu Z.Effect of vascular endothelial growth factor C(VEGF-C) gene transfer in rat model of secondary lymphedema.Vascul Pharmacol.2008;49(1):44-50.
75.Hu X,Jiang Z,Liu N.[Experimental studies of VEGF-C gene for the treatment of chronic obstructive lymphedema in mouse tail model].Zhonghua Zheng Xing Wai Ke Za Zhi.2008;24(3):207-211.
76.Rutkowski J,Moya M,Johannes J,Goldman J,Swartz M.Secondary lymphedema in the mouse tail:Lymphatic hyperplasia,VEGF-C upregulation,and the protective role of MMP-9.Microvasc Res.2006;72(3):161-171.
77.Fink A,Kaltenegger I,Schneider B,Fruhauf J,Jurecka W,Steiner A.Serum level of VEGF-D in patients with primary lymphedema.Lymphology.2004;37(4):185-189.
78.Jin dP,An A,Liu J,Nakamura K,Rockson S.Therapeutic Responses to Exogenous VEGF-C Administration in Experimental Lymphedema:Immunohistochemical and Molecular Characterization.Lymphat Res Biol.2009;7(1):47-57.
79.Yoon Y,Murayama T,Gravereaux E,Tkebuchava T,Silver M,Curry C,Wecker A,Kirchmair R,Hu C,Kearney M,Ashare A,Jackson D,Kubo H,Isner J,Losordo D.VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema.J Clin Invest.2003;111(5):717-725.
80.Feng D,Nagy JA,Brekken RA,Pettersson A,Manseau EJ,Pyne K,Mulligan R,Thorpe PE,Dvorak HF,Dvorak AM.Ultrastructural Localization of the Vascular Permeability Factor/Vascular Endothelial Growth Factor(VPF/VEGF)Receptor-2(FLK-1,KDR) in Normal Mouse Kidney and in the Hyperpermeable Vessels Induced by VPF/VEGF-expressing Tumors and Adenoviral Vectors.J.Histochem.Cytochem.2000;48(4):545-556.
81.Butler DF,Malouf PJ,Batz RC,Stetson CL.Acquired Lymphedema of the Hand Due to Herpes Simplex Virus Type 2.Arch Dermatol.1999;135(9):1125-1126.
82.Patel AR,Charles CA,Ricotti CA,Romanelli P,Connelly EA.Cutaneous Tumors,Massive Lymphadenopathy,and Secondary Lymphedema in a 16-Year-Old Boy-Quiz Case.Arch Dermatol.2008;144(9):1217-f-1222.
83.Norman SA,Localio AR,Potashnik SL,Simoes Torpey HA,Kallan MJ,Weber AL,Miller LT,DeMichele A,Solin LJ.Lymphedema in Breast Cancer Survivors:Incidence,Degree,Time Course,Treatment,and Symptoms.J.Clin.Oncol.2009;27(3):390-397.
84.Hadamitzky C,Pabst R.Acquired Lymphedema:An Urgent Need for Adequate Animal Models.Cancer Res.2008;68(2):343-345.
85.Yalcin E,Dogru D,Gone EN,Cetinkaya A,Kiper N.Yellow Nail Syndrome in an Infant Presenting with Lymphedema of the Eyelids and Pleural Effusion.Clinical Pediatrics.2004;43(6):569-572.
86.Brofman J,Hall J,Scott W,Little A.Yellow nails,lymphedema and pleural effusion.Treatment of chronic pleural effusion with pleuroperitoneal shunting.Chest.1990;97(3):743-745.
87.Szuba A,Rockson SG.Lymphedema:classification,diagnosis and therapy.Vascular Medicine.1998;3(2):145-156.
88.Southern JF,Moseieki RA,Magro C,Dickersin GR,Fallon JT,Bloch KJ.Lymphedema,lymphocytic myocarditis,and sarcoidlike granulomatosis.Manifestations of Whipple's disease.JAMA.1989;261(10):1467-1470.
89.Hayes SC,Janda M,Cornish B,Battistutta D,Newman B.Lymphedema After Breast Cancer:Incidence,Risk Factors,and Effect on Upper Body Function.J.Clin.Oncol.2008;26(21):3536-3542.
90.Wrone DA,Tanabe KK,Cosimi AB,Gadd MA,Souba WW,Sober AJ.Lymphedema After Sentinel Lymph Node Biopsy for Cutaneous Melanoma:A Report of 5 Cases.Arch Dermatol.2000;136(4):511-514.
91.Stacker SA,Vitali A,Caesar C,Domagala T,Groenen LC,Nice E,Achen MG, Wilks AF.A Mutant Form of Vascular Endothelial Growth Factor(VEGF)That Lacks VEGF Receptor-2 Activation Retains the Ability to Induce Vascular Permeability.J.Biol.Chem.1999;274(49):34884-34892.
92.Hiltunen MO,Laitinen M,Turunen MP,Jeltsch M,Hartikainen J,Rissanen TT,Laukkanen J,Niemi M,Kossila M,Hakkinen TP,Kivela A,Enholm B,Mansukoski H,Turunen A-M,Alitalo K,Yla-Herttuala S.Intravascular Adenovirus-Mediated VEGF-C Gene Transfer Reduces Neointima Formation in Balloon-Denuded Rabbit Aorta.Circulation.2000;102(18):2262-2268.
93.Jeltsch M,Karpanen T,Strandin T,Aho K,Lankinen H,Alitalo K.Vascular Endothelial Growth Factor(VEGF)/VEGF-C Mosaic Molecules Reveal Specificity Determinants and Feature Novel Receptor Binding Patterns.J.Biol.Chem.2006;281(17):12187-12195.
94.Eichmann A,Corbel C,Jaffredo T,Breant C,Joukov V,Kumar V,Alitalo K,le Douarin N.Avian VEGF-C:cloning,embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors.Development.1998;125(4):743-752.
95.Holden C.STEM CELLS:Stem Cell Candidates Proliferate.Science.2007;315(5813):761-.
96.Kaiser J.STEM CELLS:Court Rules in Favor of California Stem Cell Institute.Science.2006;312(5773):509-.
97.Ahmad S,Stewart R,Yung S,Kolli S,Armstrong L,Stojkovic M,Figueiredo F,Lako M.Differentiation of Human Embryonic Stem Cells into Corneal Epithelial-Like Cells by In Vitro Replication of the Corneal Epithelial Stem Cell Niche.Stem Cells.2007;25(5):1145-1155.
98.Holden C.EMBRYONIC STEM CELLS:Stem Cell Science Advances as Politics Stall.Science.2007;316(5833):1825-.
99.Carlo-Stella C,Tabilio A.Stem cells and stem cell transplantation.Haematologica.1996;81(6):573-587.
100.Vogel G.STEM CELL POLICY:Can Adult Stem Cells Suffice? Science.2001;292(5523):1820-1822.
101.Battula VL,Treml S,Bareiss PM,Gieseke F,Roelofs H,de Zwart P,Muller I,Schewe B,Skutella T,Fibbe WE,Kanz L,Buhring H-J.Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56,CD271,and mesenchymal stem cell antigen-1.Haematologica.2009;94(2):173-184.
102.Brachvogel B,Moch H,Pausch F,Schlotzer-Schrehardt U,Hofmann C,Hallmann R,von der Mark K,Winkler T,Poschl E.Perivascular cells expressing annexin A5 define a novel mesenchymal stem cell-like population with the capacity to differentiate into multiple mesenchymal lineages.Development.2005;132(11):2657-2668.
103.Finney M,Greco N,Haynesworth S,Martin J,Hedrick D,Swan J,Winter D,Kadereit S,Joseph M,Fu P,Pompili V,Laughlin M.Direct comparison of umbilical cord blood versus bone marrow-derived endothelial precursor cells in mediating neovascularization in response to vascular ischemia.Biol Blood Marrow Transplant.2006;12(5):585-593.
104.Jung Y,Song J,Shiozawa Y,Wang J,Wang Z,Williams B,Havens A,Schneider A,Ge C,Franceschi RT,McCauley LK,Krebsbach PH,Taichman RS.Hematopoietie Stem Cells Regulate Mesenchymal Stromal Cell Induction into Osteoblasts Thereby Participating in the Formation of the Stem Cell Niche.Stem Cells.2008;26(8):2042-2051.
105.Fazel SS,Angoulvant D,Butany J,Weisel RD,Li R-K.Mesenchymal stem cells engineered to overexpress stem cell factor improve cardiac function but have malignant potential.J.Thorac.Cardiovasc.Surg.2008;136(5):1388-1389.
106.Rivera FJ,Couillard-Despres S,Pedre X,Ploetz S,Caioni M,Lois C,Bogdahn U,Aigner L.Mesenchymal Stem Cells Instruct Oligodendrogenic Fate Decision on Adult Neural Stem Cells.Stem Cells.2006;24(10):2209-2219.
107.Williams N,Bertoncello I,Kavnoudias H,Zsebo K,McNiece I.Recombinant rat stem cell factor stimulates the amplification and differentiation of fractionated mouse stem cell populations.Blood.1992;79(1):58-64.
108.Zheng ZH,Li XY,Ding J,Jia JF,Zhu P.Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type Ⅱ collagen-reactive T cells in rheumatoid arthritis.Rheumatology.2008;47(1):22-30.
109.Iwase T,Nagaya N,Fujii T,Itoh T,Murakami S,Matsumoto T,Kangawa K,Kitamura S.Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia.Cardiovascular Research.2005;66(3):543-551.
110.Pittenger MF,Mackay AM,Beck SC,Jaiswal RK,Douglas R,Mosca JD,Moorman MA,Simonetti DW,Craig S,Marshak DR.Multilineage Potential of Adult Human Mesenchymal Stem Cells.Science.1999;284(5411):143-147.
111.Chang MG,Tung L,Sekar RB,Chang CY,Cysyk J,Dong P,Marban E,Abraham MR.Proarrhythmic Potential of Mesenchymal Stem Cell Transplantation Revealed in an In Vitro Coculture Model.Circulation.2006;113(15):1832-1841.
112.Oh JY,Kim MK,Shin MS,Lee HJ,Ko JH,Wee WR,Lee JH.The Anti-Inflammatory and Anti-Angiogenic Role of Mesenchymal Stem Cells in Corneal Wound Healing Following Chemical Injury.Stem Cells.2008;26(4):1047-1055.
113.Shibata T,Naruse K,Kamiya H,Kozakae M,Kondo M,Yasuda Y,Nakamura N,Ota K,Tosaki T,Matsuki T,Nakashima E,Hamada Y,Oiso Y,Nakamura J.Transplantation of Bone Marrow-Derived Mesenehymal Stem Cells Improves Diabetic Polyneuropathy in Rats.Diabetes.2008;57(11):3099-3107.
114.Togel F,Hu Z,Weiss K,Isaac J,Lange C,Westenfelder C.Administered mesenchymal stem cells protect against ischemie acute renal failure through differentiation-independent mechanisms.Renal Physiology.2005;289(1):F31-42.
115.Friedenstein AJ,Piatetzky-Shapiro Ⅱ,Petrakova KV.Osteogenesis in transplants of bone marrow cells.J Embryol Exp Morphol.1966;16(3):381-390.
116.Zerhouni E.EMBRYONIC STEM CELLS:Enhanced:Stem Cell Programs.Science.2003;300(5621):911-912.
117.Hawley RG.National Stem Cell Resource:Stem Cells Find a Niche.Stem Cells.2001;19(6):475-476.
118.Bach SP,Renehan AG,Potten CS.Stem cells:the intestinal stem cell as a paradigm.Carcinogenesis.2000;21(3):469-476.
119.Bernstein I,Andrews R,Zsebo K.Recombinant human stem cell factor enhances the formation of colonies by CD34+ and CD34+lin-cells,and the generation of colony-forming cell progeny from CD34+lin-cells cultured with interleukin-3,granulocyte colony-stimulating factor,or granulocyte-macrophage colony-stimulating factor.Blood.1991;77(11):2316-2321.
120.Bridenbaugh S,Kenins L,Bouliong-Pillai E,Kalberer CP,Shklovskaya E,Gratwohl A,Wodnar-Filipowicz A.Clinical stem-cell sources contain CD8+CD3+ T-cell receptor-negative cells that facilitate bone marrow repopulation with hematopoietic stem cells.Blood.2008;111(3):1735-1738.
121.Carlo-Stella C,Rizzoli V.Stem cells and stem cell factor(s).Haematologica.1995;80(1):1-4.
122.Amsalem Y,Mardor Y,Feinberg MS,Landa N,Miller L,Daniels D,Ocherashvilli A,Holbova R,Yosef O,Barbash IM,Leor J.Iron-Oxide Labeling and Outcome of Transplanted Mesenchymal Stem Cells in the Infarcted Myocardium.Circulation.2007;116(11_suppl):Ⅰ-38-45.
123.Slongo ML,Molena B,Brunati AM,Frasson M,Gardiman M,Carli M,Perilongo G,Rosolen A,Onisto M.Functional VEGF and VEGF receptors are expressed in human medulloblastomas.Neuro-oncol.2007;9(4):384-392.
124.Tomita S,Li R-K,Weisel RD,Mickle DAG,Kim E-J,Sakai T,Jia Z-Q.Autologous Transplantation of Bone Marrow Cells Improves Damaged Heart Function.Circulation.1999;100(90002):Ⅱ-247-256.
125.Hauger O,Frost EE,van Heeswijk R,Deminiere C,Xue R,Delmas Y,Combe C,Moonen CTW,Grenier N,Bulte JWM.MR Evaluation of the Glomerular Homing of Magnetically Labeled Mesenchymal Stem Cells in a Rat Model of Nephropathy.Radiology.2006;238(1):200-210.
126.Liu H,Honmou O,Harada K,Nakamura K,Houkin K,Hamada H,Kocsis JD.Neuroprotection by PIGF gene-modified human mesenchymal stem cells after cerebral ischaemia.Brain.2006;129(10):2734-2745.
127.Cancelas JA,Koevoet WLM,de Koning AE,Mayen AEM,Rombouts EJC,Ploemacher RE.Connexin-43 gap junctions are involved in multiconnexin-expressing stromal support of hemopoietie progenitors and stem cells.Blood.2000;96(2):498-505.
128.Terpstra W,Rozemuller H,Breems DA,Rombouts EJC,Prins A,FitzGerald DJP,Kreitman RJ,Wielenga JJ,Ploemacher RE,Lowenberg B,Hagenbeek A, Martens ACM.Diphtheria Toxin Fused to Granulocyte-Macrophage Colony-Stimulating Factor Eliminates Acute Myeloid Leukemia Cells With the Potential to Initiate Leukemia in Immunodeficient Mice,But Spares Normal Hemopoietic Stem Cells.Blood.1997;90(9):3735-3742.
129.van Rhenen A,Feller N,Kelder A,Westra AH,Rombouts E,Zweegman S,van der Pol MA,Waisfisz Q,Ossenkoppele GJ,Schuurhuis GJ.High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival.Clin.Cancer Res.2005;11(18):6520-6527.
130.van Rhenen A,van Dongen GAMS,Kelder A,Rombouts EJ,Feller N,Moshaver B,Walsum MS-v,Zweegman S,Ossenkoppele GJ,Jan Schuurhuis G.The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.Blood.2007;110(7):2659-2666.
131.Vroegindeweij E,Rombouts WJ,Ropela JA,Nishikawa S-I,Cupedo T,Comelissen JJ.Towards Regenerative Therapy for Thymic Insufficiency after Hematopoietic Stem Cell Transplantation:Generation of MTS24 Positive Definitive Endoderm from Murine Embryonic Stem Cells.Blood(ASH Annual Meeting Abstracts).2007;110(11):2241-.
132.Quesenberry PJ,Colvin GA,Lambert J-F.The chiaroscuro stem cell:a unified stem cell theory.Blood.2002;100(13):4266-4271.
133.Villaron E,Almeida J,Lopez-Holgado N,Alcoceba M,Sanchez-Abarca L,Sanchez-Guijo F,Alberta M,Perez-Simon J,San Miguel J,Del Canizo M.Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation.Haematologica.2004;89(12):1421-1427.
134.Azizi M,Rousseau A,Ezan E,Guyene T,Michelet S,Grognet J,Lenfant M,Corvol P,Menard J.Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.J Clin Invest.1996;97(3):839-844.
135.Azizi SA.Exploiting Nonneural Cells to Rebuild the Nervous System:From Bone Marrow to Brain.Neuroscientist.2000;6(5):353-361.
136.Paubelle E,Coppo P,Garderet L,Azizi L,Bories D,Gorin N,Fouillard L.Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation:possible enhancement of graft-vs-tumor effect.Leukemia.2005;19(9):1702-1704.
137.Prockop D,Azizi S,Colter D,Digirolamo C,Kopen G,Phinney D.Potential use of stem cells from bone marrow to repair the extracellular matrix and the central nervous system.Biochem Soc Trans.2000;28(4):341-345.
138.Rieske P,Krynska B,Azizi S.Human fibroblast-derived cell lines have characteristics of embryonic stem cells and cells of neuro-ectodermal origin.Differentiation.2005;73(9-10):474-483.
139.Toda H,Tsuji M,Nakano I,Kobuke K,Hayashi T,Kasahara H,Takahashi J,Mizoguehi A,Houtani T,Sugimoto T,Hashimoto N,Palmer TD,Honjo T, Tashiro K.Stem Cell-derived Neural Stem/Progenitor Cell Supporting Factor Is an Autocrine/Paracrine Survival Factor for Adult Neural Stem/Progenitor Cells.J.Biol.Chem.2003;278(37):35491-35500.
140.Wang Y,Yates F,Naveiras O,Ernst P,Daley GQ.Embryonic stem cell-derived hematopoietic stem cells.PNAS.2005;102(52):19081-19086.
141.Rim J-S,Mynatt RL,Gawronska-Kozak B.Mesenchymal stem cells from the outer ear:a novel adult stem cell model system for the study of adipogenesis.FASEB J.2005:04-3204fje.
142.Bryder D,Rossi DJ,Weissman IL.Hematopoietic Stem Cells:The Paradigmatic Tissue-Specific Stem Cell.Am.J.Pathol.2006;169(2):338-346.
143.Gilner JB,Walton WG,Gush K,Kirby SL.Antibodies to Stem Cell Marker Antigens Reduce Engraftment of Hematopoietic Stem Cells.Stem Cells.2007;25(2):279-288.
144.Holden C.STEM CELLS:U.S.Public Supports Stem Cell Research.Science.2005;310(5747):416b-.
145.Holden C.STEM CELLS:Prominent Researchers Join the Attack on Stem Cell Patents.Science.2007;317(5835):187-.
146.Holden C.STEM CELLS:Data on Adult Stem Cells Questioned.Science.2007;315(5816):1207a-.
147.Avots A,Harder F,Schmittwolf C,Petrovic S,Muller A.Plasticity of hematopoietic stem cells and cellular memory.Immunol Rev.2002;187:9-21.
148.Harder F,Henschler R,Junghahn I,Lamers MC,Muller AM.Human hematopoiesis in murine embryos after injecting human cord blood-derived hematopoietic stem cells into murine blastocysts.Blood.2002;99(2):719-721.
149.Harder F,Kirchhof N,Petrovic S,Wiese S,Muller A.Erythroid-like cells from neural stem cells injected into blastocysts.Exp Hematol.2004;32(7):673-682.
150.Kirchhof N,Harder F,Petrovic S,Kreutzfeldt S,Schmittwolf C,Durr M,Kirsten J,Muhl B,Merkel A,Muller A.Developmental potential of hematopoietic and neural stem cells:unique or all the same? Cells Tissues Organs.2002;171(1):77-89.
151.Wei G,Schubiger G,Harder F,Muller AM.Stem Cell Plasticity in Mammals and Transdetermination in Drosophila:Common Themes? Stem Cells.2000;18(6):409-414.
152.Cicchetti F,Gross R,Bulte J,Owen M,Chen I,Saint-Pierre M,Wang X,Yu M,Brownell A.Dual-modality in vivo monitoring of subventricular zone stem cell migration and metabolism.Contrast Media Mol Imaging.2007;2(3):130-138.
153.McQuaker I,Haynes A,Anderson S,Stainer C,Owen R,Morgan G,Lumley M,Milligan D,Fletcher J,Bessell E,Davis J,Russell N.Engraftment and molecular monitoring of CD34+ peripheral-blood stem- cell transplants for follicular lymphoma:a pilot study,J.Clin.Oncol.1997;15(6):2288-2295.
154.Owen M.Marrow stromal stem cells.J Cell Sci Suppl.1988;10:63-76.
155.Shearman M,Heyworth C,Dexter T,Haefner B,Owen P,Whetton A.Haemopoietic stem cell development to neutrophils is associated with subcellular redistribution and differential expression of protein kinase C subspecies.J.Cell Sei.1993;104(1):173-180.
156.Benayahu D,Akavia U,Shur I.Differentiation of bone marrow stroma-derived mesenehymal cells.Curr Med Chem.2007;14(2):173-179.
157.Benayahu D,Shefer G,Shur I.Insights into the transcriptional and chromatin regulation of mesenehymal stem cells in museulo-skeletal tissues.Ann Anat.2009;191(1):2-12.
155.Benayahu D,Shefer G,Shut I.Insights into chromatin remodelers in mesenehymal stem cells and differentiation.Front Biosci.2009;14:398-409.
159.Shefer G,Carmeli E,Rauner G,Yablonka-Reuveni Z,Benayahu D.Exercise running and tetracycline as means to enhance skeletal muscle stem cell performance after external fixation.J Cell Physiol.2008;215(1):265-275.
160.Shur I,Reish O,Ezra E,Benayahu D.Analysis of mesenchymal cells derived from an chondrodysplasia punctuate patient and donors.J Cell Biochem.2004;93(1):112-119.
161.Gregory CA,Reyes E,Whitney MJ,Specs JL.Enhanced Engraftment of Mesenehymal Stem Cells in a Cutaneous Wound Model by Culture in Allogenie Species-Specific Serum and Administration in Fibrin Constructs.Stem Cells.2006;24(10):2232-2243.
162.Haioun C,Lepage E,Gisselbreeht C,Coiffier B,Doyen C,Morel P,Attal M,Tilly H,Deeoninek E,Gaulard P,Reyes F.High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma.Ann.One.1998;9(suppl_1):S5-8.
163.Lopez-Onieva L,Fernandez-Minan A,Gonzalez-Reyes A.Jak/Stat signalling in niche support cells regulates dpp transcription to control germline stem cell maintenance in the Drosophila ovary.Development.2008;135(3):533-540.
164.Preto A,Cameselle-Teijeir...J,Moldes-Boullosa J,Soares P,Cameselle-Teijeir...J,Silva P,Reis-Filho J,Reyes-Santias R,Alfonsin-Barreiro N,Forteza J,Sobrinho-Simoes M.Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests.Mod Pathol.2004;17(7):819-826.
165.Reyes JMG,Fermanian S,Yang F,Zhou S-Y,Herretes S,Murphy DB,Elisseeff JH,Chuck RS.Metabolic Changes in Mesenehymal Stem Cells in Osteogenie Medium Measured by Autofluoreseence Spectroscopy.Stem Cells.2006;24(5):1213-1217.
166.Baddoo M,Hill K,Wilkinson R,Gaupp D,Hughes C,Kopen G,Phinney D.Characterization of mesenehymal stem cells isolated from murine bone marrow by negative selection.J Cell Biochem.2003;89(6):1235-1249.
167.Himes BT,Neuhuber B,Coleman C,Kushner R,Swanger SA,Kopen GC,Wagner J,Shumsky JS,Fischer I.Recovery of Function Following Grafting of Human Bone Marrow-Derived Stmmal Cells into the Injured Spinal Cord.Neurorehabil Neural Repair.2006;20(2):278-296.
165.Kopen GC,Proekop DJ,Phinney DG.Marrow stromal cells migrate throughout forebrain and cerebellum,and they differentiate into astroeytes after injection into neonatal mouse brains.PNAS.1999;96(19):10711-10716.
169.Tremain N,Korkko J,Ibberson D,Kopen GC,DiGirolamo C,Phinney DG MicroSAGE Analysis of 2,353 Expressed Genes in a Single Cell-Derived Colony of Undifferentiated Human Mesenchymal Stem Cells Reveals mRNAs of Multiple Cell Lineages.Stem Cells.2001;19(5):408-418.
170.Ng YY,van Kessel B,Lokhorst HM,Baert MRM,van den Burg CMM,Bloem AC,Staal FJT.Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity.J.Leukoc.Biol.2004;75(2):314-323.
171.Allay JA,Spencer HT,Wilkinson SL,Belt JA,Blaldey RL,Sorrentino BP.Sensitization of Hematopoietic Stem and Progenitor Cells to Trimetrexate Using Nucleoside Transport Inhibitors.Blood.1997;90(9):3546-3554.
172.Donahue RE,Wersto RP,Allay JA,Agricola BA,Metzger ME,Nienhuis AW,Persons DA,Sorrentino BP.High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34+ cells.Blood.2000;95(2):445-452.
173.Leimig T,Mann L,Martin MdP,Bonten E,Persons D,Knowles J,Allay JA,Cunningham J,Nienhuis AW,Smeyne R,d'Azzo A.Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells.Blood.2002;99(9):3169-3178.
174.Persons DA,Allay ER,Sawai N,Hargrove PW,Brent TP,Hanawa H,Nienhuis AW,Sorrentino BP.Successful treatment of murine {beta}-thalassemia using in vivo selection of genetically modified,drug-resistant hematopoietic stem cells.Blood.2003;102(2):506-513.
175.Persons DA,Allay JA,Bonifacino A,Lu T,Agricola B,Metzger ME,Donahue RE,Dunbar CE,Sorrentino BP.Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors.Blood.2004;103(3):796-803.
176.Holden C.STEM CELL POLITICS:Frist's Support Raises Odds for Passage of Stem Cell Bill.Science.2005;309(5736):858-.
177.Holden C.STEM CELLS:California Stem-Cell Institute Unveils 10-Year Plan.Science.2006;314(5797):237b-.
175.Bruder S,Jaiswal N,Picalton N,Mosca J,Kraus K,Kadiyala S.Mesenchymal stem cells in osteobiology and applied bone regeneration.Clin Orthop Relat Res.1998(355 Suppl):S247-256.
179.Binder S,Kurth A,Shea M,Hayes W,Jaiswal N,Kadiyala S.Bone regeneration by implantation of purified,culture-expanded human mesenchymal stem cells.J Orthop Res.1998;16(2):155-162.
180.Bruder S,Picalton N,Boynton R,Connolly T,Jaiswal N,Zaia J,Barry F.Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation.J Bone Miner Res.1998;13(4):655-663.
181.Cooper LF,Harris CT,Bruder SP,Kowalski R,Kadiyala S.Incipient Analysis of Mesenchymal Stem-cell-derived Osteogenesis.Journal of Dental Research.2001;80(1):314-320.
182.Jaiswal N,Haynesworth S,Caplan A,Bruder S.Osteogenic differentiation of purified,culture-expanded human mesenchymal stem ceils in vitro.J Cell Biochem.1997;64(2):295-312.
183.Jaiswal RK,Jaiswal N,Bruder SP,Mbalaviele G,Marshak DR,Pittenger MF.Adult Human Mesenchymal Stem Cell Differentiation to the Osteogenic or Adipogenic Lineage Is Regulated by Mitogen-activated Protein Kinase.J.Biol.Chem.2000;275(13):9645-9652.
184.Holtgrefe KM.Twice-Weekly Complete Decongestive Physical Therapy in the Management of Secondary Lymphedema of the Lower Extremities.Physical Therapy.2006;86(8):1128-1136.
185.Shin JW,Huggenberger R,Detmar M.Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis.Blood.2008;112(6):2318-2326.
186.Foldi-Borcsok E,Foldi M.Lymphedema and vitamins.Am.J.Clinical Nutrition.1973;26(2):185-190.
187.Petrov R,Khaitov R,Aleinikova N,Gulak L.Factors controlling stem cell recirculation.Ⅲ.Effect of the thymus on the migration and differentiation of hemopoietic stem cells.Blood.1977;49(6):865-872.
188.Trosko JE.REVIEW PAPER:Cancer Stem Cells and Cancer Nonstem Cells:From Adult Stem Cells or from Reprogramming of Differentiated Somatic Cells.Vet.Pathol.2009;46(2):176-193.
189.Tissot van Patot MC,Leadbetter G,Keyes LE,Bendrick-Peart J,Beckey VE,Christians U,Hacker P.Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness.J Appl Physiol.2005;98(5):1626-1629.
190.Kono T,Kubo H,Shimazu C,Ueda Y,Takahashi M,Yanagi K,Fujita N,Tsuruo T,Wada H,Yamashita JK.Differentiation of Lymphatic Endothelial Cells From Embryonic Stem Cells on OP9 Stromal Cells.Arterioscler.Thromb.Vasc.Biol.2006;26(9):2070-2076.
191.Borre M,Nerstrom B,Overgaard J.Association between Immunohistoehemieal Expression of Vascular Endothelial Growth Factor (VEGF),VEGF-expressing Neuroendocrine-differentiated Tumor Cells,and Outcome in Prostate Cancer Patients Subjected to Watchful Waiting.Clin.Cancer Res.2000;6(5):1882-1890.
192.Debrah AY,Mand S,Toliat MR,Marfo-Debrekyei Y,Batsa L,Nurnberg P,Lawson B,Adjei O,Hoerauf A,Pfarr K.Plasma Vascular Endothelial Growth Factor-A(VEGF-A) and VEGF-A Gene Polymorphism are Associated with Hydrocele Development in Lymphatic Filariasis.Am d Trop Med Hyg.2007;77(4):601-608.
193.Kanayama S,Nishida K,Yamato M,Hayashi R,Maeda N,Okano T,Tano Y.Analysis of soluble vascular endothelial growth factor receptor-1 secreted from cultured corneal and oral mueosal epithelial cell sheets in vitro.Br.J. Ophthalmol.2009;93(2):263-267.
194.Nishida N,Yano H,Komai K,Nishida T,Kamura T,Kojiro M.Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2are related closely to the prognosis of patients with ovarian carcinoma.Cancer.2004;101(6):1364-1374.
195.Chen Z-q,Fisher RJ,Riggs CW,Rhim JS,Lautenberger JA.Inhibition of Vascular Endothelial Growth Factor-induced Endothelial Cell Migration by ETS1 Antisense Oligonucleotides.Cancer Res.1997;57(10):2013-2019.
196.Chung I,Wong MK,Flynn G,Yu W-d,Johnson CS,Trump DL.Differential Antiproliferative Effects of Calcitriol on Tumor-Derived and Matrigel-Derived Endothelial Cells.Cancer Res.2006;66(17):8565-8573.
197.Cieslak M,Niewiarowska J,Nawrot M,Koziolkiewicz M,Stec WJ,Ciemiewski CS.DNAzymes to beta 1 and beta 3 mRNA Down-regulate Expression of the Targeted Integrins and Inhibit Endothelial Cell Capillary Tube Formation in Fibrin and Matrigel.J.Biol.Chem.2002;277(9):6779-6787.
198.Grant D,Kinsella J,Kibbey M,LaFlamme S,Burbelo P,Goldstein A,Kleinman H.Matrigel induces thymosin beta 4 gene in differentiating endothelial cells.J.Cell Sci.1995;108(12):3685-3694.
199.Li J,Wei Y,Wagner TE.In Vitro Endothelial Differentiation of Long-Term Cultured Murine Embryonic Yolk Sac Cells Induced by Matrigel.Stem Cells.1999;17(2):72-81.
200.Montrucehio G,Lupia E,Battaglia E,Del Sorbo L,Boccellino M,Biancone L,Emanuelli G,Camussi G.Platelet-Activating Factor Enhances Vascular Endothelial Growth Factor-induced Endothelial Cell Motility and Neoangiogenesis in a Murine Matfigel Model.Arterioscler.Thromb.Vasc.Biol.2000;20(1):80-88.
201.Navarro A,Perez RE,Rezaiekhaligh M,Mabry SM,Ekekezie Ⅱ.T1 {alpha}/podoplanin is essential for capillary morphogenesis in lymphatic endothelial cells.Am J Physiol Lung Cell Mol Physiol.2008;295(4):L543-551.